CL2020002622A1 - Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos - Google Patents

Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos

Info

Publication number
CL2020002622A1
CL2020002622A1 CL2020002622A CL2020002622A CL2020002622A1 CL 2020002622 A1 CL2020002622 A1 CL 2020002622A1 CL 2020002622 A CL2020002622 A CL 2020002622A CL 2020002622 A CL2020002622 A CL 2020002622A CL 2020002622 A1 CL2020002622 A1 CL 2020002622A1
Authority
CL
Chile
Prior art keywords
antibodies
graft rejection
prevention
therapies
kits
Prior art date
Application number
CL2020002622A
Other languages
English (en)
Inventor
Pascal Espie
James Rush
Boerje Haraldsson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020002622A1 publication Critical patent/CL2020002622A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos, regímenes de tratamiento, usos, kits y terapias para prevenir el rechazo de injertos en el trasplante de órganos sólidos, mediante el empleo de anticuerpos anti-CD40.
CL2020002622A 2018-04-13 2020-10-09 Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos CL2020002622A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
EP18208332 2018-11-26

Publications (1)

Publication Number Publication Date
CL2020002622A1 true CL2020002622A1 (es) 2021-04-16

Family

ID=66542473

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002622A CL2020002622A1 (es) 2018-04-13 2020-10-09 Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos

Country Status (13)

Country Link
US (2) US11780927B2 (es)
EP (1) EP3774913A1 (es)
JP (2) JP6861301B2 (es)
KR (1) KR20200143718A (es)
CN (1) CN111971307A (es)
AU (1) AU2019252858A1 (es)
BR (1) BR112020020277A2 (es)
CA (1) CA3094600A1 (es)
CL (1) CL2020002622A1 (es)
IL (1) IL277828A (es)
MX (1) MX2020010722A (es)
TW (1) TW201943731A (es)
WO (1) WO2019198019A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021021923A2 (pt) * 2019-05-08 2022-02-22 Novartis Ag Anticorpos anti-cd40 para uso no tratamento de dm1 e insulite
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
CN116888674A (zh) * 2020-10-26 2023-10-13 国家医疗保健研究所 用于评估免疫抑制剂的曲线下面积的方法及相关方法和系统
CN118234749A (zh) * 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
WO2025117849A1 (en) * 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025235683A1 (en) * 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
ES2397631T3 (es) 2003-12-25 2013-03-08 Kyowa Hakko Kirin Co., Ltd. Mutante antagonista de anticuerpos ANTI-CD40
KR20070026522A (ko) * 2004-04-27 2007-03-08 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
PT3178851T (pt) 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US11780977B2 (en) * 2020-08-10 2023-10-10 Dover Chemical Corporation Polymer compositions having an improved printable surface and related methods

Also Published As

Publication number Publication date
JP2020519634A (ja) 2020-07-02
JP6861301B2 (ja) 2021-04-21
US20240287198A1 (en) 2024-08-29
MX2020010722A (es) 2020-11-06
US11780927B2 (en) 2023-10-10
EP3774913A1 (en) 2021-02-17
BR112020020277A2 (pt) 2021-01-19
CN111971307A (zh) 2020-11-20
TW201943731A (zh) 2019-11-16
IL277828A (en) 2020-11-30
AU2019252858A1 (en) 2020-10-08
WO2019198019A1 (en) 2019-10-17
KR20200143718A (ko) 2020-12-24
CA3094600A1 (en) 2019-10-17
JP2021113190A (ja) 2021-08-05
US20210079107A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2019002011A1 (es) Anticuerpos anti-tgf-beta y su uso.
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CL2017000885A1 (es) Anticuerpos anti-ox40 humanizados y usos de los mismos
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
JOP20170170B1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
MX2023005879A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
PE20181005A1 (es) Anticuerpos biespecificos contra el a- beta humano y el receptor de transferrina humano y metodos de uso
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX2023001193A (es) Composicion de un anticuerpo inhibidor de masp-2 para usarse en el tratamiento de un padecimiento asociado con la activacion del complemento dependiente de masp-2.
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
MX2020003605A (es) Manipulación del metabolismo de triptamina.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
CL2020001123A1 (es) Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.
EA201691634A1 (ru) Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l
MX2018005589A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2017001686A (es) Anticuerpos anti-ceramida.